AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$MDWD

Rubinstein Samuel sold $7K of MDWD (indirect holdings)

Rubinstein Samuel sold 525 indirectly-held shares of MediWound Ltd. (MDWD) at $12.72 on 2026-09-01.

Original reporting
SEC EDGAR · Rubinstein Samuel
Published Sep 2, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 8:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MDWD
Neutral
high confidence
Mentioned
$MDWD
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDWDNeutralLow
01

Why it matters

The sale is small relative to market cap, unlikely to move the stock.

02

Market read

Minor insider sale with limited trading relevance.

03

What to watch

Director may have liquidity needs unrelated to company outlook.

Relevance 3/10Novelty 4/10Timing: post-market 2026-09-01

Background

Form 4 filings disclose insider trades; investors monitor them for potential signals.

Company-level read

Ticker impact

$MDWDNeutralHigh confidence
Context

Director Rubinstein Samuel sold 525 shares for $6,678, reducing holdings to zero.

Expected impact

Limited short-term impact; price likely unchanged.

Evidence & confidence

The transaction is a primary Form 4 filing with a small dollar amount, typical for directors exiting positions.

Market effects

Sector

No broader sector impact; isolated insider transaction.

Regional

None; company is micro‑cap with limited market footprint.

Global

None

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing rather than a negative signal.

Key entities

  • Company
    MediWound Ltd.

    Medical device company listed under MDWD.

  • Insider
    Rubinstein Samuel

    Director of MediWound Ltd.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MDWD insider trading history →

Related articles

$MDWDMed

A sale of 1.2 million MediWound shares is expected to close around Nov. 5.

MediWound (MDWD) announced a share sale of 1.2 million ordinary shares, with H.C. Wainwright & Co. as underwriter. The deal is expected to close around Nov. 5, 2026, with gross proceeds estimated at approximately $30 million, assuming no exercise of the underwriter’s option. The company plans to use the net proceeds for working capital and general corporate purposes.

stocktitan.net
$MDWDHighAI 8/10

Why the Pentagon Keeps Funding This Small Cap (Nasdaq: MDWD)

MediWound (MDWD) received a $3.3M award from the U.S. Department of War to develop a room-temperature-stable version of its burn treatment gel, NexoBrid. The total program budget now stands at $21.8M. NexoBrid is FDA-approved and supported by a $197M BARDA contract with Vericel (VCEL). MediWound's market cap is approximately $170M.

investegate.co.uk
$MDWDMed

MediWound Ltd. (MDWD): Financial results for Q2 2026

MediWound Ltd. (MDWD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update EscharEx ® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under it

SEC EDGAR 6-K